AbbVie Inc.
General ticker "ABBV" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $346.9B (TTM average)
AbbVie Inc. follows the US Stock Market performance with the rate: 47.4%.
Estimated limits based on current volatility of 1.4%: low 223.23$, high 229.35$
Factors to consider:
- Company included in S&P500 list
- Company pays dividends (quarterly): last record date 2025-10-15, amount 1.64$ (Y2.87%)
- Total employees count: 55000 as of 2024
- US accounted for 76.4% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Market competition, Manufacturing disruptions, Geopolitical risks, Product commercialization failure, Strategic risks and growth management
- Current price 10.4% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [153.18$, 207.08$]
- 2025-12-31 to 2026-12-31 estimated range: [164.47$, 221.36$]
Financial Metrics affecting the ABBV estimates:
- Negative: with PPE of 17.5 at the end of fiscal year the price was very high
- Positive: 7.86 < Operating profit margin, % of 16.22
- Positive: Industry earnings per price (median), % of 5.67 > 4.43
- Positive: 1.87 < Return on assets ratio (scaled to [-100,100]) of 3.07
- Negative: Shareholder equity ratio, % of 2.46 <= 18.93
- Positive: Industry operating profit margin (median), % of 20.85 > 9.92
- Positive: 5.52 < Industry operating cash flow per share per price (median), % of 8.11
- Positive: Inventory ratio change, % of -0.09 <= 0
Short-term ABBV quotes
Long-term ABBV plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $57,998.00MM | $54,497.00MM | $56,341.00MM |
| Operating Expenses | $39,881.00MM | $41,740.00MM | $47,204.00MM |
| Operating Income | $18,117.00MM | $12,757.00MM | $9,137.00MM |
| Non-Operating Income | $-4,640.00MM | $-6,507.00MM | $-5,421.00MM |
| Interest Expense | $2,044.00MM | $1,684.00MM | $2,160.00MM |
| R&D Expense | $7,207.00MM | $8,453.00MM | $15,548.00MM |
| Income(Loss) | $13,477.00MM | $6,250.00MM | $3,716.00MM |
| Taxes | $1,632.00MM | $1,377.00MM | $-570.00MM |
| Profit(Loss)* | $11,836.00MM | $4,820.00MM | $4,278.00MM |
| Stockholders Equity | $17,254.00MM | $10,360.00MM | $3,325.00MM |
| Inventory | $3,579.00MM | $4,099.00MM | $4,181.00MM |
| Assets | $138,805.00MM | $134,711.00MM | $135,161.00MM |
| Operating Cash Flow | $24,943.00MM | $22,839.00MM | $18,806.00MM |
| Capital expenditure | $695.00MM | $777.00MM | $974.00MM |
| Investing Cash Flow | $-623.00MM | $-2,009.00MM | $-20,820.00MM |
| Financing Cash Flow | $-24,803.00MM | $-17,222.00MM | $-5,211.00MM |
| Earnings Per Share** | $6.68 | $2.73 | $2.42 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.